SCHEMBL24970591

SCHEMBL24970591

CC(C)c1ccc(Cl)c2cnc(Cl)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.35
GABRA1 P14867 2/20 0.34
GABRB1 P18505 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34
GABRG3 Q99928 1/20 0.34
GABRQ Q9UN88 1/20 0.34
ACE2 Q9BYF1 1/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30164421 0.83 LMNA (0.38) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL29959057 0.83 CSNK2A1 (0.36) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL29220288 0.83 GABRA1 (0.36) LMNAGABRA1GABRB1GABRG2GABRB3
SCHEMBL24615647 0.83 ALOX5AP (0.35) LMNATP53HTTMAP4K1
SCHEMBL23593485 0.83 CSNK2A1 (0.36) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL24813077 0.83 LMNA (0.38) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL29309957 0.80 GABRP (0.42) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL23578775 0.78 LMNA (0.33) LMNAGABRA1GABRB1GABRPGABRD
SCHEMBL18101003 0.77 NOTUM (0.35)
SCHEMBL24826762 0.76 LMNA (0.36) LMNAGABRA1GABRB1GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026209-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 LMNA 4776/4885GABRA1 2728/4885GABRB1 2348/4885
US-11718602-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 LMNA 4776/4885GABRA1 2728/4885GABRB1 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.